Literature DB >> 28261854

OligoG CF-5/20 normalizes cystic fibrosis mucus by chelating calcium.

Anna Ermund1, Christian V Recktenwald1, Gudmund Skjåk-Braek2, Lauren N Meiss1, Edvar Onsøyen3, Philip D Rye3, Arne Dessen3, Astrid Hilde Myrset3, Gunnar C Hansson1.   

Abstract

The goal of this study was to determine whether the guluronate (G) rich alginate OligoG CF-5/20 (OligoG) could detach cystic fibrosis (CF) mucus by calcium chelation, which is also required for normal mucin unfolding. Since bicarbonate secretion is impaired in CF, leading to insufficient mucin unfolding and thereby attached mucus, and since bicarbonate has the ability to bind calcium, we hypothesized that the calcium chelating property of OligoG would lead to detachment of CF mucus. Indeed, OligoG could compete with the N-terminus of the MUC2 mucin for calcium binding as shown by microscale thermophoresis. Further, effects on mucus thickness and attachment induced by OligoG and other alginate fractions of different length and composition were evaluated in explants of CF mouse ileum mounted in horizontal Ussing-type chambers. OligoG at 1.5% caused effective detachment of CF mucus and the most potent alginate fraction tested, the poly-G fraction of about 12 residues, had similar potency compared to OligoG whereas mannuronate-rich (M) polymers had minimal effect. In conclusion, OligoG binds calcium with appropriate affinity without any overt harmful effect on the tissue and can be exploited for treating mucus stagnation.
© 2017 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  alginate; calcium chelation; cystic fibrosis; mucus; oligog cf-5/20

Mesh:

Substances:

Year:  2017        PMID: 28261854     DOI: 10.1111/1440-1681.12744

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  12 in total

1.  Development of an airway mucus defect in the cystic fibrosis rat.

Authors:  Susan E Birket; Joy M Davis; Courtney M Fernandez; Katherine L Tuggle; Ashley M Oden; Kengyeh K Chu; Guillermo J Tearney; Michelle V Fanucchi; Eric J Sorscher; Steven M Rowe
Journal:  JCI Insight       Date:  2018-01-11

2.  A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus.

Authors:  Courtney M Fernandez-Petty; Gareth W Hughes; Hannah L Bowers; John D Watson; Bradley H Rosen; Stacy M Townsend; Carlo Santos; Caroline E Ridley; Kengyeh K Chu; Susan E. Birket; Yao Li; Hui Min Leung; Marina Mazur; Bryan A Garcia; T Idil Apak Evans; Emily Falk Libby; Heather Hathorne; Justin Hanes; Guillermo J Tearney; John P Clancy; John F Engelhardt; William E Swords; David J Thornton; William P Wiesmann; Shenda M Baker; Steven M Rowe
Journal:  JCI Insight       Date:  2019-04-18

3.  Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study.

Authors:  Silke van Koningsbruggen-Rietschel; Jane C Davies; Tacjana Pressler; Rainald Fischer; Gordon MacGregor; Scott H Donaldson; Knut Smerud; Nils Meland; Jann Mortensen; Marie Ø Fosbøl; Damian G Downey; Astrid H Myrset; Hugo Flaten; Philip D Rye
Journal:  ERJ Open Res       Date:  2020-10-19

Review 4.  Mucus, mucins, and cystic fibrosis.

Authors:  Cameron Bradley Morrison; Matthew Raymond Markovetz; Camille Ehre
Journal:  Pediatr Pulmonol       Date:  2019-11

5.  New generation ENaC inhibitors detach cystic fibrosis airway mucus bundles via sodium/hydrogen exchanger inhibition.

Authors:  Melania Giorgetti; Nikolai Klymiuk; Andrea Bähr; Martin Hemmerling; Lisa Jinton; Robert Tarran; Anna Malmgren; Annika Åstrand; Gunnar C Hansson; Anna Ermund
Journal:  Eur J Pharmacol       Date:  2021-05-08       Impact factor: 4.432

Review 6.  Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.

Authors:  Rosa María Girón Moreno; Marta García-Clemente; Layla Diab-Cáceres; Adrián Martínez-Vergara; Miguel Ángel Martínez-García; Rosa Mar Gómez-Punter
Journal:  Antibiotics (Basel)       Date:  2021-04-23

7.  Targeted disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate oligosaccharides.

Authors:  Lydia C Powell; Manon F Pritchard; Elaine L Ferguson; Kate A Powell; Shree U Patel; Phil D Rye; Stavroula-Melina Sakellakou; Niklaas J Buurma; Charles D Brilliant; Jack M Copping; Georgina E Menzies; Paul D Lewis; Katja E Hill; David W Thomas
Journal:  NPJ Biofilms Microbiomes       Date:  2018-06-29       Impact factor: 7.290

8.  The C-terminal dimerization domain of the respiratory mucin MUC5B functions in mucin stability and intracellular packaging before secretion.

Authors:  Caroline Ridley; Michael P Lockhart-Cairns; Richard F Collins; Thomas A Jowitt; Durai B Subramani; Mehmet Kesimer; Clair Baldock; David J Thornton
Journal:  J Biol Chem       Date:  2019-09-30       Impact factor: 5.157

9.  Exploiting Mannuronan C-5 Epimerases in Commercial Alginate Production.

Authors:  Anne Tøndervik; Olav A Aarstad; Randi Aune; Susan Maleki; Philip D Rye; Arne Dessen; Gudmund Skjåk-Bræk; Håvard Sletta
Journal:  Mar Drugs       Date:  2020-11-18       Impact factor: 5.118

Review 10.  Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas.

Authors:  Hugo R de Jonge; Maria C Ardelean; Marcel J C Bijvelds; Paola Vergani
Journal:  FEBS Lett       Date:  2020-11-16       Impact factor: 3.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.